BMO Capital analyst Matthew Luchini raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $152.00 while maintaining an Outperform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE